Sara de Miguel1,2, Mirian Domenech1, Fernando González-Camacho1, Julio Sempere1, Dolores Vicioso1, Juan Carlos Sanz3,4, Luis García Comas2, Carmen Ardanuy5,6, Asunción Fenoll1, Jose Yuste1,6. 1. Spanish Pneumococcal Reference Laboratory, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain. 2. Epidemiology Department, Dirección General de Salud Pública, Comunidad de Madrid, Madrid, Spain. 3. Laboratorio Regional de Salud Pública, Comunidad de Madrid, Madrid, Spain. 4. CIBER de Epidemiología y Salud Pública, Madrid, Spain. 5. Hospital Universitario de Bellvitge, Barcelona, Spain. 6. CIBER de Enfermedades Respiratorias, Madrid, Spain.
Abstract
BACKGROUND: Introduction of pneumococcal conjugate vaccines (PCVs) has reduced the disease caused by vaccine serotypes in children, providing herd protection to adults. However, the emergence of nonvaccine serotypes is of great concern worldwide. METHODS: This study includes national laboratory data from invasive pneumococcal disease (IPD) cases that affected pediatric and adult populations during 2009-2019. The impact of implementing different vaccine strategies for immunocompetent adults by comparing Spanish regions that used the 13-valent PCV (PCV13) vs regions that used the 23-valent pneumococcal polysaccharide vaccine (PPV23) was also analyzed for 2017-2019. RESULTS: The overall reductions in IPD cases by PCV13 serotypes in children and adults were 88% and 59%, respectively, during 2009-2019, with a constant increase in serotype 8 in adults since 2015. IPD cases by additional serotypes covered by PPV23 increased from 20% in 2009 to 52% in 2019. In children, serotype 24F was the most frequent in 2019, whereas serotypes 3 and 8 accounted for 36% of IPD cases in adults. Introduction of PCV13 or PPV23 in the adult calendar of certain Spanish regions reduced the IPD cases by PCV13 serotypes by up to 25% and 11%, respectively, showing a decrease of serotype 3 when PCV13 was used. CONCLUSIONS: Use of PCV13 in children has affected the epidemiology, reducing the burden of IPD in children but also in adults by herd protection; however, the increase in serotype 8 in adults is worrisome. Vaccination with PCV13 in adults seems to control IPD cases by PCV13 serotypes including serotype 3.
BACKGROUND: Introduction of pneumococcal conjugate vaccines (PCVs) has reduced the disease caused by vaccine serotypes in children, providing herd protection to adults. However, the emergence of nonvaccine serotypes is of great concern worldwide. METHODS: This study includes national laboratory data from invasive pneumococcal disease (IPD) cases that affected pediatric and adult populations during 2009-2019. The impact of implementing different vaccine strategies for immunocompetent adults by comparing Spanish regions that used the 13-valent PCV (PCV13) vs regions that used the 23-valent pneumococcal polysaccharide vaccine (PPV23) was also analyzed for 2017-2019. RESULTS: The overall reductions in IPD cases by PCV13 serotypes in children and adults were 88% and 59%, respectively, during 2009-2019, with a constant increase in serotype 8 in adults since 2015. IPD cases by additional serotypes covered by PPV23 increased from 20% in 2009 to 52% in 2019. In children, serotype 24F was the most frequent in 2019, whereas serotypes 3 and 8 accounted for 36% of IPD cases in adults. Introduction of PCV13 or PPV23 in the adult calendar of certain Spanish regions reduced the IPD cases by PCV13 serotypes by up to 25% and 11%, respectively, showing a decrease of serotype 3 when PCV13 was used. CONCLUSIONS: Use of PCV13 in children has affected the epidemiology, reducing the burden of IPD in children but also in adults by herd protection; however, the increase in serotype 8 in adults is worrisome. Vaccination with PCV13 in adults seems to control IPD cases by PCV13 serotypes including serotype 3.
Authors: Patricia Richi; Jose Yuste; Teresa Navío; Laura González-Hombrado; Marina Salido; Israel Thuissard-Vasallo; Ana Jiménez-Díaz; Jesús Llorente; Laura Cebrián; Leticia Lojo; Martina Steiner; Tatiana Cobo; María Dolores Martín; Marta García-Castro; Patricia Castro; Santiago Muñoz-Fernández Journal: Vaccines (Basel) Date: 2021-02-28
Authors: Santiago Alfayate Miguélez; Genoveva Yague Guirao; Ana I Menasalvas Ruíz; Manuel Sanchez-Solís; Mirian Domenech Lucas; Fernando González Camacho; M Mar Ortíz Romero; Pilar Espejo García; Carmen Guerrero Gómez; Antonio Iofrío de Arce; Laura Moreno Parrado; Rosa M Sánchez Andrada; Eva Cascales Alcolea; Sebastián Lorente García; Pedro Paredes Reyes; Ángela Casquet Barceló; M Luisa López Yepes; Juan José Vigueras Abellán; Gonzalo Sanz Mateo Journal: Vaccines (Basel) Date: 2020-12-28
Authors: Stephanie W Lo; Kate Mellor; Robert Cohen; Alba Redin Alonso; Sophie Belman; Narender Kumar; Paulina A Hawkins; Rebecca A Gladstone; Anne von Gottberg; Balaji Veeraraghavan; K L Ravikumar; Rama Kandasamy; Sir Andrew J Pollard; Samir K Saha; Godfrey Bigogo; Martin Antonio; Brenda Kwambana-Adams; Shaper Mirza; Sadia Shakoor; Imran Nisar; Jennifer E Cornick; Deborah Lehmann; Rebecca L Ford; Betuel Sigauque; Paul Turner; Jennifer Moïsi; Stephen K Obaro; Ron Dagan; Idrissa Diawara; Anna Skoczyńska; Hui Wang; Philip E Carter; Keith P Klugman; Gail Rodgers; Robert F Breiman; Lesley McGee; Stephen D Bentley; Carmen Muñoz-Almagro; Emmanuelle Varon Journal: Lancet Microbe Date: 2022-08-16
Authors: Jose Manuel Tirado-Vélez; David Carreño; David Sevillano; Luis Alou; José Yuste; Adela G de la Campa Journal: Antibiotics (Basel) Date: 2021-05-13